Premium
A RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED TRIAL OF PSEUDOEPHEDRINE IN CORYZA
Author(s) -
Latte Jenny,
Taverner David,
Slobodian Peter,
Shakib Sepehr
Publication year - 2004
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.2004.04013.x
Subject(s) - pseudoephedrine , medicine , placebo , nasal congestion , confidence interval , randomized controlled trial , anesthesia , nasal administration , nasal decongestant , nose , ephedrine , surgery , pharmacology , alternative medicine , pathology
SUMMARY 1. The aim of the present study was to assess the efficacy of pseudoephedrine in coryza. 2. In a double‐blind, randomized, placebo‐controlled design, 48 adults with acute coryza received a single oral dose of 60 mg pseudoephedrine (Sudafed™; Pfizer Consumer HealthCare Group, Caringbah, NSW, Australia) or matching placebo. Before and after dosing, nasal airway resistance (NAR), nasal volume, the minimum intranasal cross‐sectional area (MCA) and the symptom of nasal congestion were measured. 3. Pseudoephedrine produced a significant decrease in NAR ( P = 0.005; 95% confidence interval (CI) 0.073, 0.383). Nasal volume increased, but this did not reach significance ( P = 0.07; 95% CI −0.842, 0.034). There was no change in MCA and symptoms. 4. In conclusion, pseudoephedrine has a moderate effect in decreasing objective measures of nasal congestion in coryza.